Comprehensive information about experimentally validated enhancers
| Enhancer ID: | E_03355 |
| Species: | Mus musculus |
| Position : | chr7:46587546-46588046 |
| Year: | 2020 |
| Title: | NFIA differentially controls adipogenic and myogenic gene program through distinct pathways to ensure brown and beige adipocyte differentiation |
| Genome Build: | mm10 |
| Enhancer Type: | Enhancer |
| Condition: | Normal |
| Disease Name: | -- |
| PMID: | 32991581 |
| MONDO: | |
| Tissue: | Skeletal muscle |
| Tissue Ontology ID: | UBERON:0001134 |
| Cell Source: | C2C12 myoblast |
| CVCL ID: | CVCL_0188 |
| Cell Type: | myoblast |
| Cell Ontology ID: | CL:0000187 |
| Experiment Type: | Enhancer activity assay, Functional perturbation assay |
| High Throughput Method: | FAIRE-seq, ChIP-seq, RNA-seq |
| Low Throughput Method: | RT-RT-qPCR, ChIP-RT-qPCR |
| Target gene : | Myod1 |
| TF name : | Nfia |
| Regulatory State : | Silenced |
| GeneName | Pathway Name | Source | Gene Number |
|---|---|---|---|
| Nfia | FOXA1 transcription factor network | pid | 45 |
| Nfia | RNA Polymerase III Abortive And Retractive Initiation | reactome | 41 |
| Nfia | RNA Polymerase III Transcription Termination | reactome | 23 |